Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection

Hookworm Infections Clinical Trial

Official title:

Phase 2 Study to Assess the Safety, Efficacy and Immunogenicity of Na-GST-1/Alhydrogel Co-administered With Different Toll-Like Receptor Agonists in Hookworm- Naïve Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03172975
• Other study ID #: H-38292
• Secondary ID: U01AI129789
• Status: Completed
• Phase: Phase 2
• Start date: March 1, 2018
• Est. completion date: September 30, 2023

Study information

• Verified date: June 2024
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.

Description:

Double blind, randomized, controlled, Phase 2 clinical trial in hookworm-unexposed adults living in the metropolitan area of Washington, DC. Subjects will receive three doses of the assigned vaccine formulation, or saline placebo, delivered intramuscularly on approximately Days 0, 56, and 112.

Subjects will be challenged with 50 infectious N. americanus larvae 4 weeks after 3rd vaccination. Fecal samples will be collected weekly starting 4 weeks post-challenge. Albendazole will be administered 20 weeks post-challenge to cure infections. Subjects will be followed until 10 months after their final vaccination.

Safety of vaccination will be measured from the time of each study vaccination (Day 0) through 14 days after each study vaccination by the occurrence of solicited injection site and systemic reactogenicity events. Safety of CHHI will be measure from the time of larval application (Day 140) through the first day of treatment with albendazole (Day 280).

Unsolicited non-serious adverse events (AEs) will be collected until approximately 1 month following each study vaccination and from study Day 140 (day of CHHI) through Day 280.

New-onset chronic medical conditions and Serious Adverse Events (SAEs) will be collected from the time of the first study vaccination through approximately 10 months after the third study vaccination (final visit). Clinical laboratory evaluations for safety will be performed on venous blood collected approximately 14 days after each vaccination and CHHI.

Immunogenicity testing will include IgG antibody responses to Na-GST-1, by a qualified indirect enzyme-linked immunosorbent assay (ELISA), on serum obtained prior to each study vaccination and CHHI, and at time points after each vaccination and after CHHI (see Appendix A); the affinity of vaccine-induced antibodies against Na-GST-1 using Surface Plasmon Resonance; the functional activity of vaccine-induced antibodies via in vitro enzyme neutralization assay; antigen-specific memory B cell responses; and, the innate immune responses to each of the TLR receptor immunostimulants.

Parasitological testing will include microscopic fecal egg detection by a qualified saline flotation technique, fecal egg counts by the McMaster method, fecal PCR for hookworm DNA, and peripheral eosinophil counts.

Recruitment and enrollment into the study will occur on an ongoing basis, with each group being recruited and vaccinated in sequence.

48 subjects will be enrolled into 4 groups of 12. Subjects will be enrolled sequentially and upon enrollment will be randomized to one of the following IP assignments in a double-blind fashion:

• Group 1 IP allocation (n=12 subjects): 12 subjects will receive 100µg Na-GST-1/Alhydrogel® delivered by IM injection in the deltoid muscle.

• Group 2 IP allocation (n=12): 12 subjects will receive Na-GST-1/Alhydrogel® plus 500µg CpG 10104 delivered by IM injection in the deltoid muscle.

• Group 3 IP allocation (n=12): 12 subjects will receive Na-GST-1/Alhydrogel® plus 5µg GLA-AF delivered by IM injection in the deltoid muscle.

• Group 4 IP allocation (n=12): 12 subjects will receive sterile saline delivered by IM injection in the deltoid muscle.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: September 30, 2023
• Est. primary completion date: May 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Males and non-pregnant females between 18 and 45 years, inclusive.

2. Good general health as determined by means of the screening procedures1.

3. Available for the duration of individual subject study participation (14 months).

4. Willingness to participate in the study as evidenced by signing the informed consent document.

5. Able to understand and comply with planned study procedures.

Exclusion Criteria:

1. Pregnancy as determined by a positive urine human choriogonadotropin (hCG) test (if female).

2. Subject unwilling to use effective contraception for a minimum of 30 days prior to vaccination and up until documentation of clearance of hookworm infection post-CHHI (if female and not surgically sterile, abstinent from intercourse with a male partner, in a monogamous relationship with a vasectomized partner, at least 2 years post-menopausal, or determined otherwise by medical evaluation to be sterile).

3. Currently lactating and breast-feeding or plans to breastfeed at any given time from the first study vaccination until clearance of hookworm infection post-CHHI (if female).

4. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, gastrointestinal, diabetes, or renal disease by history, physical examination, and/or laboratory studies.

5. Has a diagnosis of schizophrenia, bipolar disease or other major psychiatric condition that would make compliance with study visits/procedures difficult (e.g., subject with psychoses or history of suicide attempt or gesture in the 3 years before study entry, ongoing risk for suicide).

6. Known or suspected immunodeficiency or immunosuppression as a result of an underlying illness or treatment (causes for immunosuppression may include, but are not limited to, poorly-controlled diabetes mellitus, chronic liver disease, renal insufficiency, active neoplastic disease or a history of hematologic malignancy, connective tissue disease, organ transplant).

7. Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25-times the upper reference limit).

8. Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or urine dipstick testing positive for glucose or more than trace protein).

9. Laboratory evidence of hematologic disease (hemoglobin <11.1 g/dl [females] or <12.5 g/dl [males]; absolute leukocyte count <3400/mm3 or >10.8 x 103/mm3; absolute eosinophil count <500/mm3; or platelet count <140,000/mm3).

10. Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.

11. Planned participation in another investigational vaccine or drug trial within 30 days of starting this study or until the last study visit (this may include other licensed or unlicensed vaccines, drugs, biologics, devices, blood products, or medications).

12. Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 24 months.

13. Positive fecal occult blood test at screening.

14. Infection with a pathogenic intestinal helminth as determined by stool examination for ova and parasites at screening.

15. History of iron deficiency anemia or laboratory evidence of iron deficiency (serum ferritin concentration below the lower reference limit).

16. History of hypoalbuminemia.

17. History of a severe allergic reaction or anaphylaxis.

18. Severe asthma as defined by the need for daily use of inhalers, or emergency clinic visit or hospitalization within 6 months of the volunteer's expected first vaccination in the study.

19. Positive test for hepatitis B surface antigen (HBsAg).

20. Positive confirmatory test for HIV infection.

21. Positive confirmatory test for hepatitis C virus (HCV) infection.

22. Using or intends to continue using oral or parenteral corticosteroids, high-dose inhaled corticosteroids (>800 µg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs within 30 days of the volunteer's expected first vaccination in this study or planned use during the study.

23. Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to the volunteer's expected first vaccination in the study.

24. Receipt of immunoglobin or other blood products (with exception of Rho D immunoglobulin) within 90 days of the planned first study vaccination.

25. Known allergy to albendazole, amphotericin B or gentamicin.

26. History of previous infection with hookworm or continuous residence for more than 6 months in a community where hookworm is endemic.

27. Current or past scars, tattoos, or other disruptions of skin integrity at the intended site of larval application.

28. Previous receipt of the Na-GST-1/Alhydrogel® hookworm vaccine.

29. History of a surgical splenectomy.

30. Pre-existing autoimmune or antibody-mediated diseases including but not limited to:

systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia; or laboratory evidence of possible autoimmune disease determined by a positive anti-dsDNA titer, positive rheumatoid factor, and/or proteinuria (greater than trace protein on urine dipstick testing).

Related Conditions & MeSH terms

• Hookworm Infections
• Infections

Intervention

Biological:
• Na-GST-1/Alhydrogel
Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
• Na-GST-1/Alhydrogel + CPG 10104
Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
• Na-GST-1/Alhydrogel + GLA-AF
Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
• Placebo
Physiological sterile saline solution

Drug:
• Albendazole
Treatment with 3 daily oral doses of 400 mg albendazole at end of study.

Other:
• Necator americanus Larval Inoculum
50 infectious Necator americanus larvae applied via dermal application (challenge infection).

Locations

Country	Name	City	State
United States	George Washington University	Washington	District of Columbia

Sponsors (3)

Lead Sponsor	Collaborator
Baylor College of Medicine	George Washington University, National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detectable hookworm infection	Proportion of subjects with detectable hookworm eggs, at any time point, in fecal samples, as determined by microscopy using the qualified saline flotation technique	Week 20 post-CHHI
Primary	Incidence of Serious Adverse Events	Frequency of study vaccine-related Serious Adverse Events from the time of the first study vaccination through approximately 10 months after the last study vaccination.	Day 280
Primary	Incidence of solicited injection site and systemic reactogenicity	Frequency of solicited injection site and systemic reactogenicity, graded by severity, on the day of each study vaccination through 14 days after each study vaccination.	Day 14 post-vaccination
Primary	Incidence of solicited adverse events	Frequency of solicited adverse events, graded by severity, on the day of CHHI through study Day 280	Day 280
Primary	Incidence of clinical safety laboratory abnormalities	Frequency of clinical safety laboratory adverse events.	Day 14 post-vaccination
Primary	Incidence of unsolicited adverse events	Frequency of unsolicited adverse events, graded by severity, from the time of each study vaccination through approximately 1 month after each study vaccination; and from the time of CHHI through treatment with albendazole (Day 280)	Day 280
Primary	Incidence of new-onset chronic medical conditions	Frequency of new-onset chronic medical conditions through approximately 10 months after the third study vaccination.	Day 280
Primary	Incidence of Adverse Events of Special Interest	Frequency of Adverse Events of Special Interest through approximately 10 months after the third study vaccination.	Day 280
Secondary	Fecal egg counts	Fecal egg counts as determined by microscopy using the McMaster method, weekly from Weeks 5 through 20 post-CHHI	Week 5 and Week 20 post-CHHI
Secondary	Anti-Na-GST-1 IgG antibody response	Anti-Na-GST-1 IgG antibody response, by a qualified indirect enzyme-linked immunosorbent assay (ELISA) at approximately 14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose	14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose
Secondary	Anti-Na-GST-1 IgG antibody affinity	Affinity of the antibody interactions with recombinant Na-GST-1 antigen at approximately 14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose.	14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose
Secondary	Memory B cells specific for Na-GST-1	Production of memory B cells specific for Na-GST-1 on days of vaccination; approximately 7 and 14 days following each vaccination; on day of CHHI; and then 7 and 14 days, and 5, 7, 13, and 20 weeks post-CHHI.	7 and 14 days following each vaccination; on day of CHHI; and then 7 and 14 days, and 5, 7, 13, and 20 weeks post-CHHI
Secondary	Innate immune responses	Innate immune responses on days of vaccination approximately 7 and 14 days following each vaccination; on day of CHHI; and then 7 and 14 days, and 5, 7, 13, and 20 weeks post-CHHI	Approximately 7 and 14 days following each vaccination; on day of CHHI; and then 7 and 14 days, and 5, 7, 13, and 20 weeks post-CHHI